Nav: Home

Combination creates powerful central memory T cells for cellular therapy

March 25, 2020

HOUSTON -- Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab re-programs them into a stronger T cell type that persists longer than its comrades, researchers at The University of Texas MD Anderson Cancer Center report in Cancer Immunology Research, a journal of the American Association for Cancer Research.

The combination of panobinostat and interleukin-21 converts the less vigorously expanding effector T cells that attack cancer cells to a more proliferative and enduring central memory T cell type capable of self-renewal, the team found.

"Central memory T cells do almost all the things you want - they persist because they have high replicative and proliferative capacity, and they have inducible cell-killing capacity so what they see they kill very well," says senior author Cassian Yee, M.D., professor of Melanoma Medical Oncology.

Lack of persistence is one major reason cellular therapies that involve harvesting, expanding, and in some instances, genetically modifying, a patient's T cells before returning them to attack cancer fail, Yee says.

"Producing more central memory T cells in vitro can address this persistence challenge and increase the effectiveness of cellular therapies," Yee notes. Clinical trials will be required to advance his team's findings in human T cell lines. Both IL-21 and panobinostat are readily available for use.

Present cellular therapies include chimeric antigen receptor T cells - genetically modified to attack a specific target and used to treat B cell blood cancers - and tumor-infiltrating leukocytes harvested from tumors used to treat melanoma. Both techniques are in clinical trials to address other types of cancer. Yee and colleagues are developing another technique, endogenous T cells, which identifies and harvests tumor-attacking T cells in the blood. All three techniques rely on expanding the T cells in the lab before re-infusing them into patients.

Cellular therapies produce mainly effector CD8-positive T cells that are fully differentiated to attack cells bearing specific antigens. Yee, first author Junmei Wang, Ph.D., instructor in Melanoma Medical Oncology, and colleagues showed that the combination therapy re-programs these effector T cells into central memory cells.

Firing up T cell-stimulating CD28

Their research confirmed that IL-21 activates STAT3, a protein that then connects with the promoter region of the gene encoding the T cell stimulatory protein CD28, firing up CD28.

Their team found that in effector T cells, this process is blocked by histone proteins that intertwine with DNA to form chromatin. This "closed" chromatin status covers the promoter regions on CD28 that STAT hits to activate it.

Acetyl groups that connect to histone proteins cause a more "open" status for gene transcription. Drugs called histone deacetylase (HDAC) inhibitors protect the acetyl group connection and allow transcription factors to connect with genes' promoter regions to activate them.

The team treated human T cell lines with the HDAC inhibitor vorinostat and IL-21. With vorinostat relaxing the chromatin, IL-21-generated STAT3 activated CD28, resulting in expansion of T cells bearing the markers for central memory T cells. The main markers are CD28 and CD62L expression.

A second round of experiments using the HDAC inhibitor panobinostat, which is less toxic to T cells than vorinostat, produced even stronger central memory T cell expansion. The combination was given at the start of T cell expansion procedures.

To further confirm the central memory properties of treated cells, the team assessed expression of genes involved in differentiating T cells and found expression of central-memory differentiating genes to be highly expressed on the identified central memory cells generated by the combination.

A patent application has been filed based on this research, which is being managed in accordance with MD Anderson's conflict-of-interest policies
Co-authors with Yee and Wang are: Farah Hasan, Jungsun Park, Ph.D., Ke Pan, Ph.D., Cara Haymaker, Ph.D., and Chantale Bernatchez, Ph.D., of Melanoma Medical Oncology; Haiyan Li, Ph.D., and Stephanie Watowich, Ph.D., of Immunology; Amanda Frey, Ph.D., University of Washington; and Dean Lee, M.D., Ph.D., Nationwide Children's Hospital, Columbus, Ohio. Hasan is a graduate student in the MD Anderson/UTHealth Graduate School of Biomedical Sciences.

This research was supported by the Parker Institute for Cancer Immunotherapy, Stand Up To Cancer-Cancer Research Institute Dream Team and a grant from the National Institute of Allergy and Infectious Diseases (RO1AI109294).

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 49 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report's "Best Hospitals" survey. It has ranked as one of the nation's top two hospitals for cancer care since the survey began in 1990, and has ranked first 14 times in the last 17 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Follow MDAnderson News on Twitter

University of Texas M. D. Anderson Cancer Center

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.